Briacell Therapeutics Corp
Publicly observedPhiladelphia, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Philadelphia | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Briacell Therapeutics Corp | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | S4APLQN63FL6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2023Publicly observed
NIH SBIR/STTR award: An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.
USD 947,870.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2023Publicly observed
NIH SBIR/STTR award: An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.
USD 1,106,781.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.